Document is current

Article History

Received: 30 September 2024

Accepted: 31 December 2024

First Online: 16 January 2025

Declarations

:

: The study was approved by the ethics review board of the Medical University of Vienna (approval no. 2081/2022) and conducted according to institutional and national standards and compliant to the Helsinki Declaration of 1964 with all its amendments. Due to the retrospective nature of the study, no written informed consent was obtained in line with institutional regulations.

: Maximilian J. Mair has received research funding from Bristol-Myers Squibb and travel support from Pierre Fabre. Georg Widhalm has received honoraria for advisory board participation from Servier. Franziska Eckert has received travel grants and honoraria for lectures or advisory board from Dr. Sennewald Medizintechnik and Servier. Felix Sahm is co-founder and shareholder of Heidelberg Epignostix GmbH. Anna Sophie Berghoff has research support from Daiichi Sankyo, Roche and honoraria for lectures, consultation or advisory board participation from Roche Bristol-Meyers Squibb, Merck, Daiichi Sankyo, AstraZeneca, CeCaVa, Seagen, Alexion, Servier as well as travel support from Roche, Amgen and AbbVie.Matthias Preusser has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Janssen, Servier, Miltenyi, Böhringer-Ingelheim, Telix, Medscape. Nathalie L. Albert has received honoraria for lectures, consultation or advisory board participation from Novartis, Advanced Accelerator Applications, Servier, OncLive, Medsir and Telix Pharmaceuticals, and research funding from Novocure and Telix Pharmaceuticals.